ONCOLOGY-BEYOND ALLOPATHY
نویسندگان
چکیده
منابع مشابه
Oncology in midlife and beyond.
The onset of the menopause is often a time when women's concerns can act as a powerful trigger to encourage healthy modifications in lifestyle which will maintain, or improve, their general health. This document aims to help women to understand their potential risks, to encourage them to find proactive preventive strategies by modifying some of their attitudes, and to use health resources (when...
متن کاملHDAC inhibitors: applications in oncology and beyond
Inhibitors of the histone deacetylases (HDACIs), a class of small molecules primarily involved in the modification of epigenetic regulation, have been exploited widely for their anti-cancer effects and/or chemo/ radio-sensitization properties. The mechanisms of action of several HDACIs have been unraveled that include modifications of histone acetylation status influencing gene expression and/o...
متن کاملBeyond Checkpoint Inhibitors: The Next Generation of Immunotherapy in Oncology
Introduction Over the past 5 years, immunotherapy has brought a revolution of changes in how numerous cancers are treated. Using the immune system to target tumors, largely by suppressing the programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) pathways, has been effective for melanoma, non–small cell lung cancer, head and neck cancer, renal cell carci...
متن کاملPart I: Liver function in oncology: biochemistry and beyond.
The liver has a key role in the metabolism (ie, inactivation or activation) of many commonly used anticancer agents-cytotoxics or new biological agents. Therefore, assessment of liver function is a fundamental part of initial work-up and management of patients with cancer. An understanding of the meaning of conventional serum biochemical testing of liver function and status, what variables they...
متن کاملNeuro-oncology, a decade of temozolomide and beyond.
It has been a decade since the regulatory approval of temozolomide, the first drug specifically developed for the treatment of malignant glioma. Initially, only a conditional approval was granted by the US FDA based on a high radiological response rate in recurrent anaplastic astrocytoma, while in glioblastoma the observed responses in two pivotal studies were only 5 and 8%, respectively [1–3]....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: UP STATE JOURNAL OF OTOLARYNGOLOGY AND HEAD AND NECK SURGERY
سال: 2017
ISSN: 2321-3450
DOI: 10.36611/upjohns/17.6